Collexis Announces $2.7 Million Private Placement

    Strategic Initiatives on Track

    COLUMBIA, S.C., December 17 /CNW/ - Collexis (OTCBB:CLXS), a leading
developer of high definition search and discovery software, announced today
that it has raised gross proceeds of $2.7 million through the private
placement of 3.6 million shares of restricted common stock to institutional
and other accredited investors at $0.75 cents a share.

    "We are gratified that both existing and new investors, including board
members, have recognized the significant progress we are making towards our
strategic initiatives and are enthusiastic about the exciting opportunities
that lie ahead as we further develop our technological solutions," said
William Kirkland, Collexis CEO. "This financing will allow us to expand our
core platforms, launch our social networking community, make selected
strategic acquisitions and for working capital purposes."

    Over the past few months, Collexis has added a number of high-profile
institutions such as the Mayo Clinic and the California Institute for
Biosciences (QB3) to its client base. Collexis also completed the acquisition
of its long time development partner, SyynX Solutions GmbH, and announced the
pending launch of the world's first pre-populated professional social network
for life science researchers, called at the 2007 Frankfurt

    About Collexis Holdings, Inc.

    Named a Trend-Setting product of 2007 by KMWorld, Collexis Holdings,
Inc., a leading developer of high definition search and discovery software
since 1999, is headquartered in Columbia, South Carolina (USA), with three
subsidiaries: Collexis Inc. in Columbia, South Carolina, USA; Collexis, B.V.
in Geldermalsen, The Netherlands; and SyynX Solutions GmBH in Cologne,
Germany. Collexis proprietary technology builds conceptual profiles of text,
called Fingerprints, from documents, websites, e-mails and other digitized
content and matches them with a comprehensive list of pre-defined
"fingerprinted" concepts to make research results more relevant and efficient.
This matching of concepts eliminates the ambiguity and lack of priority
associated with word searches. The results are often described as "finding
needles in many haystacks." Through this novel approach, Collexis can build
unique applications to search, index and aggregate information as well as
prioritize, trend and predict data based on sources in multiple industries
without the limitations of language or dialect. Collexis's current clients in
the public, private and academic sectors include the Mayo Clinic; Johns
Hopkins University; University of California, San Francisco; University of
South Carolina; Erasmus University Library; Merck & Co.; Bristol-Myers Squibb;
Lockheed Martin; the World Health Organization; Wellcome Trust; the National
Institutes of Health; and the U.S. Department of Defense. For more
information, please visit

    Forward-Looking Statements

    Some of the statements made in this press release may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are based on
management's current expectations and include known and unknown risks,
uncertainties and other factors, many of which the company is unable to
predict or control, that may cause the company's actual results or performance
to differ materially from any future results or performance expressed or
implied by such forward-looking statements. These statements involve risks and
uncertainties, including risks and uncertainties associated with the
acquisition of SyynX; with whether the benefits of the SynnX acquisition will
occur as anticipated, with the planned launch of the company's social
networking and collaboration platform for the biomedical research community;
and with whether the company will in fact be able to make additional strategic
acquisitions. These risks and uncertainties are in addition to other factors
detailed from time to time in the company's filings with the SEC, including
the section entitled "Risk Factors" in its transition report on Form 10-KSB
for the period ended June 30, 2007. The company cautions investors that any
forward-looking statements made by the company are not necessarily indicative
of future performance. The company is not responsible for updating the
information contained in this press release beyond the published date, or for
changes made to this document by wire services or Internet services.

For further information:

For further information: Investment Relations CEO Cast Michael Wachs,
+1-212-732-4300 or Media Relations Avalanche Strategic
Communications Denyse Dabrowski, + 1-201-488-0049 + 1-201-916-7122 mobile

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890